Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Raphael J Landovitz und 25 weiteren Autor:innen. Beteiligte Einrichtung: UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIMH NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Background
Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) has high efficacy against HIV-1 acquisition. Seventy-two prospective studies of daily oral F/TDF PrEP were conducted to evaluate HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.
Methods
HIV-1 incidence was calculated from incident HIV-1 diagnoses after PrEP initiation and within 60 days of discontinuation. Tenofovir concentrations in dried blood spots (DBS), drug resistance, and bone/renal safety indicators were evaluated in a subset of studies.
Results
Among 17 274 participants, there were 101 cases with new HIV-1 diagnosis (.77 per 100 person-years; 95% confidence interval [CI]: .63–.94). In 78 cases with resistance data, 18 (23%) had M184I or V, 1 (1.3%) had K65R, and 3 (3.8%) had both mutations. In 54 cases with tenofovir concentration data from DBS, 45 (83.3%), 2 (3.7%), 6 (11.1%), and 1 (1.9%) had average adherence of <2, 2−3, 4−6, and ≥7 doses/wk, respectively, and the corresponding incidence was 3.9 (95% CI: 2.9–5.3), .24 (.060–.95), .27 (.12–.60), and .054 (.008–.38) per 100 person-years. Adherence was low in younger participants, Hispanic/Latinx and Black participants, cisgender women, and transgender women. Bone and renal adverse event incidence rates were 0.69 and 11.8 per 100 person-years, respectively, consistent with previous reports.
Conclusions
Leveraging the largest pooled analysis of global PrEP studies to date, we demonstrate that F/TDF is safe and highly effective, even with less than daily dosing, in diverse clinical settings, geographies, populations, and routes of HIV-1 exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, USA.
- Gilead Sciences, Inc, Foster City, California, USA.
- Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA.
- US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- University of Washington, Seattle, Washington, USA.
- Instituto Nacional de Infectologia Evandro Chagas/Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Förderung
- Medical Research Council
- NIMH NIH HHS
- NIAAA NIH HHS
- NIH HHS
- Gilead Sciences, Inc.
- California HIV-1 Research Program
- National Institutes of Health
- National Institutes of Mental Health
Zitieren
APA
Landovitz, R. J., Tao, L., Yang, J., de Boer, M., Carter, C., Das, M., Baeten, J. M., Liu, A., Hoover, K. W., Celum, C., Grinsztejn, B., Morris, S., Wheeler, D. P., Mayer, K. H., Golub, S. A., Bekker, L. G., Diabaté, S., Hoornenborg, E., Myers, J., …, & Global F/TDF PrEP Study Team (2024). Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae143
Vancouver
Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, et al. Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae143
BibTeX
@article{Landovitz2024,
author = {Landovitz, Raphael J and Tao, Li and Yang, Juan and de Boer, Melanie and Carter, Christoph and Das, Moupali and Baeten, Jared M and Liu, Albert and Hoover, Karen W and Celum, Connie and Grinsztejn, Beatriz and Morris, Sheldon and Wheeler, Darrell P and Mayer, Kenneth H and Golub, Sarit A and Bekker, Linda-Gail and Diabaté, Souleymane and Hoornenborg, Elske and Myers, Janet and Leech, Ashley A and McCormack, Sheena and Chan, Philip A and Sweat, Michael and Matthews, Lynn T and Grant, Robert and Global F/TDF PrEP Study Team, Global F/TDF PrEP Study Team},
title = {Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae143}
}
EUVIMED